Research Papers:

Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes

Rui Yang, Li Y. An, Qin F. Miao, Feng M. Li, Yong Han, Hui X. Wang, Dang P. Liu, Rong Chen and Sha Q. Tang _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:35894-35916. https://doi.org/10.18632/oncotarget.9116

Metrics: PDF 1819 views  |   HTML 5038 views  |   ?  


Rui Yang1, Li Y. An2, Qin F. Miao1, Feng M. Li1, Yong Han1, Hui X. Wang1, Dang P. Liu1, Rong Chen3 and Sha Q. Tang1

1 School of Medicine, Southeast University, Nanjing, People’s Republic of China

2 Jiangsu Key Laboratory of Molecular and Fuctional Imaging, Department of Radiology, Zhongda Hospital, Nanjing, People’s Republic of China

3 Department of Oncology, Zhongda Hospital, Nanjing, People’s Republic of China

Correspondence to:

Sha Q. Tang, email:

Keywords: LCSCs; CD90; TMs; targeting therapy; hyperthermia therapy

Received: December 02, 2015 Accepted: April 16, 2016 Published: April 29, 2016


Aim: To investigate the use of thermosensitive magnetoliposomes (TMs) loaded with magnetic iron oxide (Fe3O4) and the anti-cancer stem cell marker CD90 (CD90@TMs) to target and kill CD90+ liver cancer stem cells (LCSCs).

Methods: The hepatocellular carcinoma cell line Huh7 was used to separate CD90+ LCSCs by magnetic-activated cell sorting. CD90@TMs was characterized and their ability to target CD90+ LCSCs was determined. Experiments were used to investigate whether CD90@TMs combined with magnetic hyperthermia could effectively eliminate CD90+ LCSCs.

Results: The present study demonstrated that CD90+ LCSCs with stem cells properties were successfully isolated. We also successfully prepared CD90@TMs that was almost spherical and uniform with an average diameter of 130±4.6 nm and determined that magnetic iron oxide could be incorporated and retained a superparamagnetic response. CD90@TMs showed good targeting and increased inhibition of CD90+ LCSCs in vitro and in vivo compared to TMs.

Conclusion: CD90@TMs can be used for controlled and targeted delivery of anticancer drugs, which may offer a promising alternative for HCC therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9116